[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer

The ESPAC1 and ESPAC1-Plus trials in 2001 and 2004 respectively established surgery and six months of adjuvant chemotherapy as the standard of care for empirically resectable pancreatic cancer. This protocol was confirmed repeatedly over the last 25 years, leading to an enormous increase in the volume of patients being treated with surgery and adjuvant chemotherapy. The development of improved cancer treatment strategies requires that randomised controlled trials that aimed to be practice changing should include the best current standard of care as the control group.